 "pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing")
Led by double-digit growth in its India formulations business, especially specialty drugs, Vadodara-based Alembic Pharmaceuticals Ltd (APL) posted a 24.92 per cent rise in its consolidated net profit for the third quarter of financial year 2020-21.
The company saw its consolidated profit after tax (PAT) stand at Rs 292.57 crore in Q3 of FY21, up from Rs 234.19 crore in the said quarter last year. APL's consolidated total income on the other hand grew by 8.87 per cent in the said quarter at Rs 1316.86 crore, up from Rs 1209.54 crore in Q3 of previous FY'20.
According to Shaunak Amin,
